Batu Biologics Announces FDA Development Plans for ValloVax™

Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine
Company Plans to Develop “Next Generation” Govallo Cancer Vaccine, VG-1000, for American Population

Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme in our developmental experiments.

Read the full article at businesswire.com

0